GNBT - Gapping up on this:
Generex's Subsidiary Presents Promising Data on Efficacy of DNA Vaccine Technology at the NIH Conference
Monday January 5, 9:01 am ET
Therapy Cures Aggressive Cancer in Half of Mice Treated
TORONTO, Jan. 5 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, announced today that Antigen Express, Inc., its wholly-owned subsidiary, recently presented a poster on its DNA vaccine technology for cancer at the NIH Conference titled, "Innovative Administrative Systems for Vaccines." Robert Humphreys, M.D., Ph.D., Executive VP and Chief Scientific Officer of Antigen Express delivered the presentation in a poster that illustrated the benefits of using Antigen Express's proprietary and patented Ii protein antisense reagents to induce a T helper cell response to prostate cancer antigens. The therapy cured about half of the mice with an aggressive, poorly immunogenic cancer.
ADVERTISEMENT
The conference also highlighted several methods of mucosal vaccination. Generex's technology, with RapidMist administration of vaccines, was identified as potentially proving useful in therapies for autoimmune diseases such as multiple sclerosis or in the control of asthma. In such a scenario, doctors and patients could prefer use of RapidMist, the company's needle-free technology.
About Generex
Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs. Generex acquired Antigen Express in August. 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act |
